Recommended content

Minor cannabinoids making major inroads targeting specific medical conditions

New information and research about minor cannabinoids – among the 100-200 that have been identified – is helping treat different health and wellness conditions and allowing cannabis companies to sell a wider variety of products.

The products go beyond the typical THC and CBD offerings currently on store shelves, and they incorporate lesser cannabinoids such as CBN and THCV.


The new products – including edibles and vapes – allow cannabis companies to appeal to consumers seeking ways to address conditions such as obesity, sleeplessness and nausea.

“We’re better trying to understand which plants elicit what effects and how to consistently provide that to consumers so we can get away from all the meaningless strain names and get right to the point of how do you want this plant to help you feel,” said Mike Hennesy, vice president of innovation at Colorado-based edibles maker Wana Brands.


Read full article on Marijuana Business Daily

Follow us on Instagram or join us on facebook page

Be first to rate

Marijuana Business Daily

More news